Press "Enter" to skip to content

Posts tagged as “Rozlytrek”

Health Canada grants market authorization to ROZLYTREK® (entrectinib) for ROS1-positive, locally advanced or metastatic non-small cell lung cancer patients, not previously treated with crizotinib(1) – Canada NewsWire

admin 0

Health Canada grants market authorization to ROZLYTREK® (entrectinib) for ROS1-positive, locally advanced or metastatic non-small cell lung cancer patients, not previously treated with crizotinib(1)  Canada NewsWire “lung cancer” – Google News

FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors – BioSpace

admin 0

FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors  BioSpace SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Genentech, Inc., a member of…

BRIEF-FDA Approves Genentech’S Rozlytrek For People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer And NTRK Gene Fusion-Positive Solid Tumors – Reuters

admin 0

BRIEF-FDA Approves Genentech’S Rozlytrek For People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer And NTRK Gene Fusion-Positive Solid Tumors  Reuters Aug 15 (Reuters) – Roche Holding AG: * FDA APPROVES GENENTECH’S…